A company founded by two Waterloo Engineering graduates has been granted approval to sell a device for predicting post-surgery complications in the huge United States market.
FluidAI, which is based in Kitchener and has 85 employees, was launched by alumni Youssof Helwa (BASc ’15, nanotechnology engineering, MASc ’18, electrical and computer engineering) and Amr Abdelgawad (BASc ’16, nanotechnology engineering, MBET ’17) in 2014.
Its flagship product, Origin, is the result of five years of development, refinement, studies and trials on four continents. The company has so far raised over $20 million in funding.
Helwa, the CEO, described recent approval by the US Food and Drug Administration as a “major milestone” that gives the company access to the largest healthcare market in the world.
“It took a lot of work (and) a lot of resources for us to come to where we are today,” he said in an interview with BetaKit.
FluidAI is focused on the development of technology to predict complications after general and gastrointestinal surgery by analyzing patient data and fluids.